DDInter1476 DDInter786
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy.[L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments.
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexamethasone
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Brigatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Pirbuterol (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Pirbuterol (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir